Sarepta posts first Phase 4 ENDURE real-world safety data for Elevidys in Duchenne patients at NMSG 2026

PUBT · 1d ago
Sarepta posts first Phase 4 ENDURE real-world safety data for Elevidys in Duchenne patients at NMSG 2026
  • Sarepta Therapeutics flagged new neuromuscular data slated for presentation at the Neuromuscular Study Group meeting on Sept. 25-27, 2026.
  • First Phase 4 ENDURE interim results will outline real-world safety for Elevidys use in Duchenne patients treated in routine clinical care.
  • Poster analyses also examine how treatment timing relates to outcomes, aiming to inform patient selection and care pathways.
  • Separate early-stage updates will cover safety and drug exposure for SRP-1003 in DM1, SRP-1001 in FSHD1.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sarepta Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609240830BIZWIRE_USPR_____20260924_BW471682) on September 24, 2026, and is solely responsible for the information contained therein.